Comparative study between intravesical gemcitabine versus bacillus Calmette– Guérin in high risk superficial bladder cancer

Objectives. To study the efficacy and safety of intravesical gemcitabine (GEM) in comparison to intravesical bacillus Calmette–Guérin (BCG) for patients with high risk non-muscle invasive tumors.

Methods. 100 patients with histologically confirmed non-muscle invasive bladder cancer (carcinoma in situ, Ta, T1), in the high-risk group of urothelial carcinoma, treated in the outpatient clinic of the Urology between 2021 and 2023 who received adjuvant intravesical therapy were simply randomized to group A (BCG group) and group B (GEM group) following single postoperative intravesical instillation of (GEM) chemotherapy after transurethral resection of bladder tumor, each group contained 50 patients were evaluated.

Results. All patients were evaluated for a follow-up of 24 months after treatment. There is no significant statistical difference in clinical and pathological characteristics between the groups. There was no statistically significant difference in the recurrence rate and progression rate of the disease in each group respectively (p = 0.2, 0.06) also overall diseasefree rate (p = 0.128). Regarding safety, free cases of any adverse events were clinically and statistically significant between both groups (p = 0.002). There were statistically significant differences between groups A and B in grade II (hematuria, fever) and grade III (allergy, BCGosis) adverse effects respectively (p = 0.001, 0.003). Although grade I complications were more in the BCG arm, but it was not statistically significant.

Conclusion. The adjuvant intravesical GEM chemotherapy has equal efficacy for BCG immuno-therapy in the treatment of high-risk superficial bladder cancer patients following transurethral resection of bladder tumor. In addition, GEM is associated with reduced local and systemic toxicity compared with BCG.

1. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27(3):289–93. DOI: 10.1007/s00345-009-0383-3

2. Patton S.E., Hall M.C., Ozen H. Bladder cancer. Curr Opin Oncol 2002;14(3):265–72. DOI: 10.1097/00001622-200205000-00003

3. Addeo R., Caraglia M., Bellini S. et al. Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010;28(4):543–8. DOI: 10.1200/JCO.2008.20.8199

4. Van Lingen A.V., Witjes J.A. Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opin Biol Ther 2013;13(10):1371–85. DOI: 10.1517/14712598.2013.824421

5. Gandhi N.M., Morales A., Lamm D.L. Bacillus Calmette–Guérin immunotherapy for genitourinary cancer. BJU Int 2013;112(3):288–97. DOI: 10.1111/j.1464-410X.2012.11754.x

6. Shelley M.D., Jones G., Cleves A. et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int 2012;109(4):496–505. DOI: 10.1111/j.1464-410X.2011.10880.x

7. Lamm D.L. Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol 2003;21:4259–60. DOI: 10.1200/JCO.2003.08.099

8. Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23:3.

9. Laufer M., Ramalingam S., Schoenberg M.P. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003;21:697–703. DOI: 10.1200/JCO.2003.09.028

10. Lorusso V., Pollera C.F., Antimi M. et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Cooperative Group on Bladder Cancer. Eur J Cancer 1998;34:1208. DOI: 10.1016/s0959-8049(98)00030-6

11. Dalbagni G., Russo P., Bochner B. et al. Phase II trial of intravesical gemcitabine in bacillus Calmette–Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006;24(18):2729–34. DOI: 10.1200/JCO.2005.05.2720

12. Bassi P., De Marco V., Tavolini I.M. et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to Bacillus Calmette–Guérin therapy. Urol Int 2005;75(4):309–13. DOI: 10.1159/000089164

13. Bartoletti R., Cai T., Gacci M. et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 2005;66(4):726–31. DOI: 10.1016/j.urology.2005.04.062

14. Jones G., Cleves A., Wilt T.J. et al. Intravesical gemcitabine for nonmuscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:CD009294. DOI: 10.1002/14651858.CD009294.pub2

15. Di Lorenzo G., Perdona S., Damiano R. et al. Gemcitabine versus bacillus Calmette–Guérin after initial bacillus Calmette–Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010;116(8):1893–900. DOI: 10.1002/ cncr.24914

16. Babjuk M., Burger M., Zigeuner R. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64(4):639–53. DOI: 10.1016/j.eururo.2013.06.003

17. O’Donnell M.A. Practical applications of Intravesical chemotherapy and immunotherapy in high risk patients with superficial bladder cancer. Urol Clin North Am 2005;32:121–31. DOI: 10.1016/j.ucl.2005.01.003

18. Miller T.P., Li Y., Getz K.D. et al. Using electronic medical record data to report laboratory adverse events. Br J Haematol 2017;177(2):283–6. DOI: 10.1111/bjh.14538

19. Shelley M.D., Kynaston H., Court J. et al. A systematic review of intravesical Bacillus Calmette–Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88(3):209–16. DOI: 10.1046/j.1464-410x.2001.02306.x

20. Shelley M.D., Wilt T.J., Court J. et al. Intravesical bacillus Calmette–Guérin is superior to mitomycin C in reducing tumor recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93(4):485–90. DOI: 10.1111/j.1464-410X.2003.04655.x

21. Han R.F., Pan J.G. Can intravesical Bacillus Calmette–Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67(6):1216–23. DOI: 10.1016/j.urology.2005.12.014

22. Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette– Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90–5. DOI: 10.1097/00005392-200301000-00023

23. Herr H.W., Dalbagni G. Defining bacillus Calmette–Guérin refractory superficial bladder tumors. J Urol 2003;169(5):1706–8. DOI: 10.1097/01.ju.0000062605.92268.c6

24. Soloway M.S. Introduction and overview of intravesical therapy for superficial bladder cancer. Urology 1988;31(3 Suppl):5–16.

25. Gardmark T., Jahnson S., Wahlquist R. et al. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and Bacillus Calmette–Guérin in patients with high-risk bladder cancer. BJU Int 2007;99(4):817–20. DOI: 10.1111/j.1464-410X.2006.06706.x

26. Nissenkorn I., Herrod H., Soloway M.S. Side effects associated with intravesical mitomycin. J Urol 1981;126(5):596–7. DOI: 10.1016/S0022-5347(17)54642-X

27. Shang P.F., Kwong J., Wang Z.P. et al. Intravesical Bacillus Calmette–Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2011;5:CD006885. DOI: 10.1002/14651858.CD006885.pub2